Market LIVE
Published markets; coverage varies by country
Product profile · United States

CORLANOR

 ·  Patent Litigation & Settlement History ↓

IngredientIVABRADINE HYDROCHLORIDE
Application typeNDA
Application206143
Product001
Dosage formTABLET
RouteORAL
StrengthEQ 5MG BASE
Approval date2015-04-15
Marketing statusDiscontinued
Status event—
ApplicantAMGEN INC
Product source

Current GenericRadar decision

Year—
SelectionEXISTING_GENERIC
ReviewCOMPLETED
Anchor type—
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2021-12-30
Status event—

ANDA 214051/001 Final 2021-12-30; FDA RLD brand or first generic source. Exact RLD product and competing same-day/earlier ANDAs should be checked.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
73616492026-02-22DS/DP/U U-1694———
———
73616502026-02-22DS/DP/U U-1694———
———
78798422026-02-22DS/DP/U U-1694———
———
73616492026-08-22— ————
—2026-08-22—
73616502026-08-22— ————
—2026-08-22—
78798422026-08-22— ————
—2026-08-22—
78679962026-12-12DS/DP/U U-1694———
———
78679962027-06-12— ————
—2027-06-12—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
214051 / 001FINAL_APPROVAL · FINAL_APPROVED2021-12-30—INGENUS PHARMACEUTICALS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213366 / 001FINAL_APPROVAL · FINAL_APPROVED2022-10-05—ANNORA PHARMA PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213442 / 001FINAL_APPROVAL · FINAL_APPROVED2023-11-29—ZYDUS PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213276 / 001FINAL_APPROVAL · FINAL_APPROVED2024-09-05—BIONPHARMA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215238 / 001FINAL_APPROVAL · FINAL_APPROVED2024-11-08—ALEMBIC PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213483 / 001FINAL_APPROVAL · FINAL_APPROVED2025-04-28—MSN LABORATORIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 6 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
214051 / 001INGENUS PHARMACEUTICALS LLCFINAL_APPROVAL · FINAL_APPROVED2021-12-30 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213366 / 001ANNORA PHARMA PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2022-10-05 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213442 / 001ZYDUS PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2023-11-29 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213276 / 001BIONPHARMA INCFINAL_APPROVAL · FINAL_APPROVED2024-09-05 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215238 / 001ALEMBIC PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2024-11-08 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213483 / 001MSN LABORATORIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2025-04-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.